Article Text

Download PDFPDF
A risk prediction model of linezolid-induced thrombocytopenia for elderly patients with chronic kidney disease is urgently needed
  1. Xiaohua Zhou1,
  2. Hongjian Ji2
  1. 1Department of Nephrology, Yancheng Third People's Hospital, Yancheng, China
  2. 2School of Pharmacy, Jiangsu Vocational College of Medicine, Yancheng, China
  1. Correspondence to Dr Xiaohua Zhou, Department of Nephrology, Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People's Hospital, Yancheng, China; zhouxiaohua1983{at}126.com

Statistics from Altmetric.com

We read with interest the recently published article by Qin et al.1 The authors stated that a range of factors were risk factors of linezolid-induced thrombocytopenia (LI-TP) in elderly patients. These risk factors were estimated glomerular filtration rate (eGFR), being admitted to an intensive care unit (ICU), baseline platelet counts and concomitant piperacillin-tazobactam. Qin et al established an LI-TP risk prediction model based on the results of multivariate logistic regression analysis which exhibited a perfect discriminative power. As a nephrology clinician with more than 12 years experience, it is my opinion that appropriate administration of antimicrobials is vital for patients with chronic kidney disease who have a bacterial infection.

According to guidelines from the Infectious Diseases Society of America (IDSA), vancomycin, linezolid and teicoplanin as first line treatment are recommended to …

View Full Text

Footnotes

  • Contributors XXZ and HJJ conceived of the study and drafted the manuscript. XXZ participated in its design and coordination and helped to draft the manuscript. Both authors read and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.